Lipodystrophy syndrome in patients with HIV infection: quality of life issues (Q34248411)

31 July 2017

1 reference

title

Lipodystrophy syndrome in patients with HIV infection: quality of life issues (English)

1 reference

31 July 2017

1 reference

E Martínez

1

1 reference

31 July 2017

M A Garcia-Viejo

series ordinal

2

1 reference

31 July 2017

L Blanch

series ordinal

3

1 reference

31 July 2017

J M Gatell

series ordinal

4

1 reference

31 July 2017

1 January 2001

1 reference

31 July 2017

1 reference

31 July 2017

24

1 reference

31 July 2017

3

1 reference

31 July 2017

157-166

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200124030-00001

31 July 2017

0 references

cites work

Liposuction for protease-inhibitor-associated lipodystrophy

1 reference

12 December 2020

Performance of a new, HIV/AIDS-targeted quality of life (HAT-QoL) instrument in asymptomatic seropositive individuals

1 reference

12 December 2020

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

12 December 2020

Use of the MQoL-HIV with asymptomatic HIV-positive patients.

1 reference

12 December 2020

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

1 reference

12 December 2020

The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy

1 reference

12 December 2020

Opportunistic infections occurring during highly active antiretroviral treatment

1 reference

12 December 2020

Fat distribution and metabolic changes in patients with HIV infection

1 reference

12 December 2020

The effect of protease inhibitors on weight and body composition in HIV-infected patients

1 reference

12 December 2020

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

1 reference

12 December 2020

Effect of indinavir on HIV-related wasting

1 reference

12 December 2020

Studies of body composition and fat distribution in HIV-infected and control subjects

1 reference

12 December 2020

Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations

1 reference

12 December 2020

A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection

1 reference

12 December 2020

Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy

1 reference

12 December 2020

Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy

1 reference

12 December 2020

Assessing the needs and quality of life of patients with HIV infection: development of the HIV Overview of Problems-Evaluation System (HOPES)

1 reference

12 December 2020

The case for more cautious, patient-focused antiretroviral therapy

1 reference

12 December 2020

The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients.

1 reference

12 December 2020

Strategies for long-term success in the treatment of HIV infection

1 reference

12 December 2020

Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.

1 reference

12 December 2020

Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial

1 reference

12 December 2020

Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus G

1 reference

12 December 2020

Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities

1 reference

12 December 2020

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

12 December 2020

Comprehensive clinical care: managing HIV as a chronic illness.

1 reference

12 December 2020

A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution

1 reference

12 December 2020

Hypertriglyceridemia in the acquired immunodeficiency syndrome

1 reference

12 December 2020

A new HIV/AIDS-targeted quality of life (HAT-QoL) instrument: development, reliability, and validity

1 reference

12 December 2020

Protease inhibitors in HIV infection. Lipodystrophy may be a consequence of prolonged survival

1 reference

12 December 2020

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

12 December 2020

Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy

1 reference

12 December 2020

Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome

1 reference

12 December 2020

Changes in quality of life among persons with HIV infection

1 reference

12 December 2020

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

1 reference

12 December 2020

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

12 December 2020

Treatments for wasting in patients with the acquired immunodeficiency syndrome

1 reference

12 December 2020

Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy

1 reference

12 December 2020

Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome.

1 reference

12 December 2020

Hit HIV-1 hard, but only when necessary

1 reference

12 December 2020

Metabolic abnormalities and use of HIV-1 protease inhibitors

1 reference

12 December 2020

Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome

1 reference

12 December 2020

Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.

1 reference

12 December 2020

Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV.

1 reference

12 December 2020

Psychological interventions in infection with the human immunodeficiency virus

1 reference

12 December 2020

Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy

1 reference

12 December 2020

10.2165/00002018-200124030-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference